Treatment of hepatitis E virus

@article{Dalton2016TreatmentOH,
  title={Treatment of hepatitis E virus},
  author={H. Dalton and N. Kamar},
  journal={Current Opinion in Infectious Diseases},
  year={2016},
  volume={29},
  pages={639–644}
}
Purpose of review Over the last 10 years, it has become apparent that hepatitis E virus (HEV) is a pathogen of global significance. In contrast to HEV in the developing world, HEV in developed countries is caused by HEV genotypes 3 and 4, which are enzoonotic with a porcine primary host and cause both acute and chronic infection. Chronic infection occurs in the immunosuppressed, including transplant recipients, and untreated can cause rapidly progressive cirrhosis. Recent findings Ribavirin has… Expand
Hepatitis E virus: A potential threat for patients with liver disease and liver transplantation.
TLDR
Recommendation is to treat chronic HEV patients for 3 months, asses serum HEV RNA and stool HEVRNA and stop therapy if both are undetectable and studies are required to determine which other antiviral agents than ribavirin and (PEG-)IFN are of clinical utility in treating HEV in the minority of patients who do not respond to Ribavirin. Expand
The Epidemiology and Prevention of Hepatitis E Virus Infection
TLDR
Clinical observations support the effectiveness of ribavirin therapy from chronic HEV, and an expanded animal reservoir of Hepeviridae is found that is human pathogens and strains that are only animal pathogens. Expand
Dosing ribavirin in hepatitis E‐infected solid organ transplant recipients
TLDR
An overview of HEV epidemiology, its mode of transmission and clinical manifestations, as well as its treatment by ribavirin with a focus on the drug's pharmacokinetics and dosing is provided. Expand
Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients
TLDR
Hepatitis E virus infection in immunocompromised patients such as solid organ transplant recipients does not necessarily respond to reduction of immunosuppressive therapy, but can be effectively and safely treated with ribavirin. Expand
Immunological Manifestations of Hepatitis E-Associated Acute and Chronic Liver Failure and Its Regulatory Mechanisms
Hepatitis E virus (HEV) is a common cause of viral hepatitis in developing countries, most commonly transmitted through the fecal-oral route. The virus is mainly of genotypes (GT) 1 and GT2Expand
From hepatitis A to E: A critical review of viral hepatitis
TLDR
The epidemiology, pathogenesis, clinical presentation, diagnostic tools and current medication regimens of hepatitis A, B, C, D and E are described, with a focus on upcoming treatment options and the role of liver transplantation. Expand
Hepatitis E virus replication and interferon responses in human placental cells
TLDR
It is observed that HEV is capable of completing the full viral life cycle in placental‐derived cells (JEG‐3), and differential tissue‐specific host responses to HEV genotypes are shown, adding to understanding of the mechanisms contributing to fatal outcomes of HEV infections during pregnancy. Expand
Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes
TLDR
Prevalence of chronic HEV infection was high in a cohort of renal transplant recipients with elevated liver enzymes and was associated with significant liver impairment and the occurrence of renal injury, and Ribavirin treatment was effective. Expand
Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
TLDR
This work focuses on the mutagenic effect of RBV on HEV intrahost populations, and how HEV is able to overcome lethal mutagenesis. Expand
Hepatitis E virus (HEV)—The Future
TLDR
The elimination of HEV from pigs, other animals and humans is consistent with the One Health concept, preventing subclinical infections in the animals as well as preventing transmission to humans and disease. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 29 REFERENCES
Treatment of chronic hepatitis E in a patient with HIV infection.
TLDR
The clinical and laboratory response to antiviral therapy for chronic HEV infection in a patient also infected with HIV is described, with a 48-year-old bisexual male with HIV- 1 infection. Expand
Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy
TLDR
The presence of the 1634R variant at Ribavirin initiation does not lead to absolute ribavirin resistance, and the proportion increased in patients whose treatment failed, but did not compromise the response to a secondribavirin treatment. Expand
In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
TLDR
This first investigation of intrahost HEV population evolution indicates that RBV causes HEV mutagenesis in treated patients and that an emergence of distinct mutants within the viral population occurs during RBV therapy. Expand
Fatal Accelerated Cirrhosis after Imported HEV Genotype 4 Infection
TLDR
It is reported that imported HEV genotype 4 infection is reported in a patient during which cirrhosis and fatal hepatic decompensation ensued, culminating in esophageal variceal hemorrhage. Expand
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients
TLDR
An early response to ribavirin can be used to define the optimal duration of therapy in the setting of HEV infection. Expand
Ribavirin for chronic hepatitis E virus infection in transplant recipients.
TLDR
This retrospective, multicenter study showed that ribavirin as monotherapy may be effective in the treatment of chronic HEV infection; a 3-month course seemed to be an appropriate duration of therapy for most patients. Expand
Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients
TLDR
HEV-associated glomerulonephritis seems to be an HEV-related extrahepatic manifestation in solid-organ transplant patients during HEV infection that improved and proteinuria decreased after HEV clearance. Expand
A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.
TLDR
The G1634R mutation appears to increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of ribavirin. Expand
Hepatitis E virus and neurological injury
TLDR
The reported cases of HEV-associated neurological injury are reviewed, possible pathogenic mechanisms are discussed, and perspectives on future directions and research questions are presented. Expand
Treatment of autochthonous acute hepatitis E with short‐term ribavirin: a multicenter retrospective study
  • J. Péron, F. Abravanel, +11 authors N. Kamar
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2016
TLDR
It is hypothesized that early short‐term treatment of acuteHEV infection may be useful for patients with risk factors or undergoing chemotherapy, and Ribavirin is now the antiviral treatment of choice in solid‐organ‐transplant recipients with chronic HEV infection. Expand
...
1
2
3
...